Today: 27 February 2026
Subscribe
Browse Category

NYSE:JNJ 17 November 2025 - 9 December 2025

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson shares closed at $201.62 on December 8, 2025, up nearly 40% year to date and valuing the company at about $486 billion. The stock surged after a Q3 earnings beat, raised full-year guidance, and a surprise plan to spin off its DePuy Synthes orthopaedics unit. JNJ remains a key driver of recent Dow gains. Technical models project up to 16% further upside by March 2026.
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.
9 December 2025
······
Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson shares traded at $202.48 on December 8, 2025, near a 52-week high and up nearly 35% over the past year. The company raised its 2025 sales guidance to $93–94 billion and EPS to about $10.80–$10.90 after beating Q2 and Q3 expectations. Analysts’ 12-month targets average just above the current price, with a consensus “Buy” rating. J&J faces Stelara patent loss, talc lawsuits, and MedTech pricing pressure in China.
8 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson closed Friday at just over $201, near its 52-week high of $207.81, with a market cap around $486 billion. The company reported positive CAR-T therapy data at ASH 2025 and gained access to China’s new drug reimbursement catalog. The board declared a Q4 dividend of $1.30 per share. About 67,670 federal talc lawsuits remain unresolved after a judge rejected J&J’s latest $10 billion settlement offer.
8 December 2025
·
Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson shares closed at $201.90 on December 5, 2025, less than 3% below their 52-week high. The stock has climbed about 35% over the past year, fueled by earnings beats, acquisitions, and new clinical data. The company faces large talc litigation verdicts and plans to spin off its orthopaedics unit. Market capitalization stands near $485 billion.
6 December 2025
··
Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson shares closed at $201.93 on December 5, 2025, near a record high after climbing about 35% over the past year. The stock’s 2025 rally outpaced major indexes, driven by strong earnings and portfolio changes, but ongoing talc litigation remains a risk. JNJ trades at roughly 19 times trailing earnings, with a market cap near $480 billion. Institutional ownership is close to 70%.
6 December 2025
·
Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson shares closed near $201 on December 5, 2025, up about 40% year-to-date and just below record highs. Guggenheim raised its price target to $227 after strong Q3 results and increased full-year guidance. Institutional ownership remains high amid ongoing litigation and a planned spinoff. Most analyst targets now cluster near current prices.
5 December 2025
·
Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson traded near $206 on Wednesday, close to its 52-week high after a 40% rally this year. Guggenheim reiterated a Buy rating and $206 target, citing strong multiple myeloma trial results. Barclays raised its target to $197 but kept an Equal Weight rating. The company launched a vision-care campaign with Naomi Watts and received European approval for its autoimmune drug IMAAVY.
4 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson closed at $206.92 on December 2, just below its record high of $207.56 from November 26. The company’s market cap stands near $500 billion after a 30% year-to-date stock surge, outpacing the S&P 500. Recent gains follow strong earnings, higher 2025 guidance, a new EU drug approval, and a $3.05 billion oncology acquisition.
2 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson closed at $206.92 on Friday, just below its all-time intraday high of $207.81 set in late November. The stock has gained 17.6% over the past three months and 43.5% year-to-date, far outpacing the S&P 500. Market capitalization stands near $500 billion. Shares open December 1 with investors watching for new analyst commentary and ongoing legal and spin-off risks.
30 November 2025
·
Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Johnson & Johnson stock surged to an all-time high close of $207.56 on November 26, 2025, lifting its market value above $500 billion for the first time. Shares are up about 45% year-to-date, far outpacing the S&P 500. The rally follows strong Q3 results, raised guidance, and momentum from new drugs, despite ongoing litigation and product setbacks. JNJ now trades at 19.8 times trailing earnings.
30 November 2025
·
Johnson & Johnson (JNJ) Stock Near Record Highs: Today’s News, Earnings, Dividend and Talc Risks – November 29, 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: Today’s News, Earnings, Dividend and Talc Risks – November 29, 2025

Johnson & Johnson shares closed just above $206 on November 29, 2025, near a record high and pushing the company’s market value to $498 billion. The stock has returned over 40% year-to-date, fueled by earnings beats, a planned orthopedics spin-out, and steady dividend growth. Institutional investors reported mixed moves, with Schroder trimming its stake and New York State Common Retirement Fund also reducing holdings.
29 November 2025
···
Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Johnson & Johnson shares closed at $206.92 on November 28, just below their 52-week high of $207.81. The stock is up about 43–47% year-to-date, far outpacing the S&P 500. Oncology sales rose 20.6% in the first nine months of 2025, reaching $18.5 billion. Analyst consensus remains broadly positive, with recent price targets mostly below current levels.
29 November 2025
··
Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson shares closed just below a 52-week high near $208 on November 28, giving the company a $500 billion market cap. The stock is up 17.6% over three months and 43% year-to-date, far outpacing the S&P 500. Recent moves include a $3.05 billion Halda Therapeutics acquisition and plans to spin off DePuy Synthes. Norway’s sovereign wealth fund has taken a multibillion-dollar stake.
28 November 2025
··
Johnson & Johnson (JNJ) Stock Today – November 26, 2025: 12‑Day Rally Pushes Shares Toward $500 Billion Valuation

Johnson & Johnson (JNJ) Stock Today – November 26, 2025: 12‑Day Rally Pushes Shares Toward $500 Billion Valuation

Johnson & Johnson shares traded near $207.11 Wednesday afternoon, just below their all-time high, putting the company’s market value around $498–500 billion. The stock has gained about 47% year-to-date, outpacing the S&P 500, and is on track for a record 13-day winning streak. November’s nearly 10% rise would mark its best month since 2021.
26 November 2025
·
Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson traded near $206 per share on Monday, just below its 12-month high, ahead of Tuesday’s key ex-dividend date for a $1.30 per share payout. The stock is up over 7% in November, outpacing the broader market. Options activity spiked Monday, with call volume jumping 468% to about 201,000 contracts. JNJ’s market cap stands just under $500 billion.
25 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
1 … 5 6 7 8
Go toTop